New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
15:03 EDTARRY, FRXArray BioPharma hires new Chief Scientific Officer, VP of R&D
Array BioPharma (ARRY) announced the appointments of Nicholas Saccomano, Ph.D., as Chief Scientific Officer and Robert Winkler, M.D., as VP of Clinical Research and Development. Saccomano most recently served as Chief Technology Officer at SomaLogic and as Chief Scientific Officer at Bend Research. Winkler most recently served as VP of Global Clinical Development and Operations at Aptalis Pharma, which was recently acquired by Forest Labs (FRX).
News For ARRY;FRX From The Last 14 Days
Check below for free stories on ARRY;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
17:02 EDTFRXActavis files to sell 843,085 ordinary shares
The offering is related to shares that may be issued upon the exercise of stock options granted under certain equity plans of Forest Laboratories to former employees or former directors of Forest.
09:27 EDTARRYOn The Fly: Pre-market Movers
Subscribe for More Information
July 31, 2014
18:08 EDTARRYArray BioPharma receives orphan status for ovarian cancer treatment
Reference Link
July 23, 2014
06:41 EDTARRYArray BioPharma shares attractive at current levels, says Piper Jaffray
Piper Jaffray says shares of Array BioPharma are attractive at current levels ahead of Phase III data readouts for binimetinib in melanoma, selumetinib in Kras-mutant lung, thyroid and uveal melanoma, and filanesib in multiple myeloma. Piper sees the biggest overhang on Array shares as being the financing requirement and it notes that binimetinib could be returned to the company from current partner Novartis (NVS). Nonetheless, it feels investors should take a "serious look" at Array and keeps an Overweight rating on the stock with a $9 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use